Literature DB >> 19871532

ANTIBODY FORMATION IN VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC POLYSACCHARIDES.

M Heidelberger1, C M Macleod, S J Kaiser, B Robinson.   

Abstract

1. A modification of the microanalytical quantitative precipitin method, five to ten times as sensitive as the older procedure, has been used to measure the type-specific antibody response in human beings. Injections of type-specific pneumococci or equivalent amounts of their type-specific polysaccharides led to comparable antibody production. In general, the few hundredths of a milligram of polysaccharides injected functioned as extraordinarily powerful antigens. 2. Subcutaneous injections of the polysaccharides were as effective as intracutaneous, and the resulting antibody levels, which were highly variable individually, remained relatively constant for 5 to 8 months, gradually tapering off during periods of observation that exceeded 2 years in some instances. 3. After the injection of several type-specific polysaccharides widely diverse combinations of selective and non-selective responses were observed. 4. Booster doses had little or no effect in increasing circulating antibody, even after 2 years. A tentative explanation is given of this unexpected result. 5. Possibly because they frequently harbor pneumococci, normal human beings appear to be in serological equilibrium with the C-antigen of pneumococcus, since in most instances the quite appreciable anti-C content of their sera remained relatively constant during periods of a year or longer. Many of the sera also contained antibody to S VII.

Entities:  

Year:  1946        PMID: 19871532      PMCID: PMC2135606     

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS : SECOND PAPER.

Authors:  M Heidelberger; O T Avery
Journal:  J Exp Med       Date:  1924-08-31       Impact factor: 14.307

2.  QUANTITATIVE CHEMICAL STUDIES ON COMPLEMENT OR ALEXIN : I. A METHOD.

Authors:  M Heidelberger
Journal:  J Exp Med       Date:  1941-05-31       Impact factor: 14.307

3.  QUANTITATIVE STUDIES ON THE PRECIPITIN REACTION : THE DETERMINATION OF SMALL AMOUNTS OF A SPECIFIC POLYSACCHARIDE.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1932-03-31       Impact factor: 14.307

4.  THE IMMUNOLOGICAL PROPERTIES OF THE HETEROPHILE ANTIGEN AND SOMATIC POLYSACCHARIDE OF PNEUMOCOCCUS.

Authors:  W F Goebel; M H Adams
Journal:  J Exp Med       Date:  1943-05-01       Impact factor: 14.307

5.  QUANTITATIVE CHEMICAL STUDIES ON COMPLEMENT OR ALEXIN : IV. ADDITION OF HUMAN COMPLEMENT TO SPECIFIC PRECIPITATES.

Authors:  M Heidelberger; M Mayer
Journal:  J Exp Med       Date:  1942-03-01       Impact factor: 14.307

6.  THE SPECIFIC POLYSACCHARIDES OF TYPES I, II, AND III PNEUMOCOCCUS : A REVISION OF METHODS AND DATA.

Authors:  M Heidelberger; F E Kendall; H W Scherp
Journal:  J Exp Med       Date:  1936-09-30       Impact factor: 14.307

7.  SPECIFIC AND NON-SPECIFIC POLYSACCHARIDES OF TYPE IV PNEUMOCOCCUS.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1931-04-30       Impact factor: 14.307

8.  THE PRECIPITIN REACTION BETWEEN TYPE III PNEUMOCOCCUS POLYSACCHARIDE AND HOMOLOGOUS ANTIBODY : II. CONDITIONS FOR QUANTITATIVE PRECIPITATION OF ANTIBODY IN HORSE SERA.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1935-03-31       Impact factor: 14.307

9.  MOUSE-PROTECTIVE TITERS OF SERA OF VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC POLYSACCHARIDES.

Authors:  A W Walter; E L Schenkein; W D Sutliff
Journal:  J Exp Med       Date:  1946-03-31       Impact factor: 14.307

10.  CHEMICAL AND IMMUNOLOGICAL PROPERTIES OF A SPECIES-SPECIFIC CARBOHYDRATE OF PNEUMOCOCCI.

Authors:  W S Tillett; W F Goebel; O T Avery
Journal:  J Exp Med       Date:  1930-11-30       Impact factor: 14.307

View more
  18 in total

1.  [On the origin of normal antibodies].

Authors:  G F SPRINGER
Journal:  Klin Wochenschr       Date:  1960-06-01

2.  [Newer method of determination and localization of antibodies; with a special reference to the combination of electrophoresis and serologic antibody-determination].

Authors:  F SCHEIFFARTH; G BERG; W FRENGER
Journal:  Klin Wochenschr       Date:  1956-02-01

3.  Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

Review 4.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

5.  Immunochemical properties of oligosaccharide-protein conjugates with Klebsiella-K2-specificity. II. Protective capacity of the conjugates and anti-conjugate antibodies against infection with Klebsiella pneumoniae 01:K2 in mice.

Authors:  H Geyer; S Schlecht; K Himmelspach
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

Review 6.  Structure, function and immunochemistry of bacterial exopolysaccharides.

Authors:  R Weiner; S Langille; E Quintero
Journal:  J Ind Microbiol       Date:  1995-10

7.  Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.

Authors:  G S Giebink; J V Grebner; Y Kim; P G Quie
Journal:  Yale J Biol Med       Date:  1978 Sep-Oct

8.  Studies on the induction of immunological unresponsiveness to pneumococcal polysaccharide in mice.

Authors:  G W Siskind; J G Howard
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

9.  IMPROVED METHODS FOR THE PREPARATION OF THE SPECIFIC POLYSACCHARIDES OF PNEUMOCOCCUS.

Authors:  M Heidelberger; C M Macleod; H Markowitz; A S Roe
Journal:  J Exp Med       Date:  1950-03-31       Impact factor: 14.307

10.  Studies on the capacity of some polysaccharides to elicit antibody formation in man.

Authors:  P Z ALLEN; E A KABAT
Journal:  J Exp Med       Date:  1957-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.